Revolution Medicines, Inc.
RVMD
55 insider filings · Latest: Sep 29, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| May 26, 2026 | May 26 8:46 PM | ANTHONY MANCINI | Proposed Sale | 3,121 | $151.56 | $473.0K | — | View → |
| Apr 27, 2026 | Apr 29 9:50 PM | Anthony ManciniChief Global Commercialization Officer | Sale | 3,120 | $132.41 | $413.1K | 54,400(D) | View → |
| Apr 27, 2026 | Apr 27 8:32 PM | ANTHONY MANCINI | Proposed Sale | 3,120 | $135.30 | $422.1K | — | View → |
| Apr 15, 2026 | Apr 17 11:26 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Sale | 120,000 | $150.09 | $18.0M | 276,698(D) | View → |
| Apr 15, 2026 | Apr 15 8:53 PM | MARK A GOLDSMITH | Proposed Sale | 120,000 | $147.01 | $17.6M | — | View → |
| Mar 25, 2026 | Mar 27 12:04 AM | Anthony ManciniChief Global Commercialization Officer | Sale | 37,450 | $95.56 | $3.6M | 54,400(D) | View → |
| Mar 25, 2026 | Mar 27 12:01 AM | Mancini Anthony | Proposed Sale | 37,450 | $95.56 | $3.6M | — | View → |
| Mar 17, 2026 | Mar 19 10:57 PM | Lin WeiChief Medical Officer | Sale | 2,073 | $99.48 | $206.2K | 101,366(D) | View → |
| Mar 17, 2026 | Mar 19 10:57 PM | Stephen Michael KelseyPresident, Research and Development | Sale | 4,302 | $99.48 | $428.0K | 295,398(D) | View → |
| Mar 17, 2026 | Mar 19 10:56 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Sale | 12,871 | $99.48 | $1.3M | 276,698(D) | View → |
| Mar 17, 2026 | Mar 19 10:56 PM | Margaret A HornChief Operating Officer | Sale | 4,583 | $99.48 | $455.9K | 157,570(D) | View → |
| Mar 17, 2026 | Mar 19 10:55 PM | Jack AndersChief Financial Officer | Sale | 2,753 | $99.48 | $273.9K | 125,512(D) | View → |
| Mar 19, 2026 | Mar 19 10:54 PM | Jeff CisliniGeneral Counsel | Sale | 1,163 | $97.44 | $113.3K | 58,518(D) | View → |
| Mar 17, 2026 | Mar 19 10:54 PM | Jeff CisliniGeneral Counsel | Sale | 1,795 | $99.48 | $178.6K | 59,681(D) | View → |
| Mar 17, 2026 | Mar 19 10:53 PM | Xiaolin WangEVP, Clinical Development | Sale | 2,010 | $99.48 | $200.0K | 116,063(D) | View → |
| Mar 19, 2026 | Mar 19 8:22 PM | JEFFREY TODD CISLINI | Proposed Sale | 1,163 | $98.11 | $114.1K | — | View → |
| Mar 16, 2026 | Mar 13 11:41 PM | Wang Xiaolin | Proposed Sale | 2,282 | $99.59 | $227.3K | — | View → |
| Mar 16, 2026 | Mar 13 11:40 PM | Wei Lin | Proposed Sale | 2,288 | $99.59 | $227.9K | — | View → |
| Mar 16, 2026 | Mar 13 11:38 PM | Kelsey Stephen Michael | Proposed Sale | 3,901 | $99.59 | $388.5K | — | View → |
| Mar 16, 2026 | Mar 13 11:36 PM | Horn Margaret A | Proposed Sale | 4,722 | $99.59 | $470.3K | — | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | Apr 29 9:50 PM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 3,120 | $33.62 | 109,230(D) | View → |
| Apr 15, 2026 | Apr 17 11:26 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 120,000 | $4.73 | 424,085(D) | View → |
| Mar 25, 2026 | Mar 27 12:04 AM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 37,450 | $33.62 | 112,350(D) | View → |
| Mar 1, 2026 | Mar 4 2:11 AM | Xiaolin WangEVP, Clinical Development | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:10 AM | Lin WeiChief Medical Officer | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:09 AM | Stephen Michael KelseyPresident, Research and Development | Grant/Award | 47,600 | $102.02 | 47,600(D) | View → |
| Mar 2, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 30,000 | $4.09 | 47,708(D) | View → |
| Mar 1, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Grant/Award | 128,600 | $102.02 | 128,600(D) | View → |
| Mar 1, 2026 | Mar 4 2:08 AM | Margaret A HornChief Operating Officer | Grant/Award | 47,600 | $102.02 | 47,600(D) | View → |
| Mar 1, 2026 | Mar 4 2:08 AM | Jeff CisliniGeneral Counsel | Grant/Award | 32,500 | $102.02 | 32,500(D) | View → |
| Mar 1, 2026 | Mar 4 2:07 AM | Jack AndersChief Financial Officer | Grant/Award | 45,400 | $102.02 | 45,400(D) | View → |
| Feb 6, 2026 | Feb 10 10:30 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 24,010 | $0.54 | 144,493(D) | View → |
← Previous
Page 2 of 2